U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Gastric Carcinoma

MedGen UID:
1631246
•Concept ID:
C4688320
•
Neoplastic Process

Definition

Gastric carcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Gastric Carcinoma

Professional guidelines

PubMed

The treatment landscape for gastroesophageal adenocarcinomas.
Sonbol MB, Pathak S, Bekaii-Saab T
Clin Adv Hematol Oncol 2022 Mar;20(3):169-177. PMID: 36607347
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2018 Nov;34(6):465-468. doi: 10.1097/MOG.0000000000000475. PMID: 30303856

Recent clinical studies

Etiology

Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E
BMC Gastroenterol 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. PMID: 37986043Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2018 Nov;34(6):465-468. doi: 10.1097/MOG.0000000000000475. PMID: 30303856
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Diagnosis

Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
Refractory Chylothorax and Lymphedema Caused by Advanced Gastric Cancer.
Nagano N, Suzuki M, Tamura K, Kobayashi S, Kojima Y, Naka G, Iikura M, Izumi S, Takeda Y, Sugiyama H
Intern Med 2019 Nov 1;58(21):3143-3148. Epub 2019 Jul 10 doi: 10.2169/internalmedicine.2351-18. PMID: 31292374Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Zollinger-Ellison syndrome: classical considerations and current controversies.
Epelboym I, Mazeh H
Oncologist 2014 Jan;19(1):44-50. Epub 2013 Dec 6 doi: 10.1634/theoncologist.2013-0369. PMID: 24319020Free PMC Article
Recent advances in endoscopic ultrasonography.
Nakazawa S
J Gastroenterol 2000;35(4):257-60. doi: 10.1007/s005350050342. PMID: 10777153

Therapy

Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M
Int J Mol Med 2020 Feb;45(2):279-297. Epub 2019 Dec 4 doi: 10.3892/ijmm.2019.4418. PMID: 31894255Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K
Lancet Oncol 2017 Nov;18(11):1512-1522. Epub 2017 Oct 13 doi: 10.1016/S1470-2045(17)30604-6. PMID: 29037983
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment.
Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K
Cancer Sci 2023 Jan;114(1):16-24. Epub 2022 Oct 19 doi: 10.1111/cas.15609. PMID: 36197901Free PMC Article
Immunotherapeutic advances in gastric cancer.
Yoneda A, Kuroki T, Eguchi S
Surg Today 2021 Nov;51(11):1727-1735. Epub 2021 Feb 15 doi: 10.1007/s00595-021-02236-2. PMID: 33590326
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K
Lancet Oncol 2017 Nov;18(11):1512-1522. Epub 2017 Oct 13 doi: 10.1016/S1470-2045(17)30604-6. PMID: 29037983
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Docetaxel.
Cortes JE, Pazdur R
J Clin Oncol 1995 Oct;13(10):2643-55. doi: 10.1200/JCO.1995.13.10.2643. PMID: 7595719

Clinical prediction guides

The treatment landscape for gastroesophageal adenocarcinomas.
Sonbol MB, Pathak S, Bekaii-Saab T
Clin Adv Hematol Oncol 2022 Mar;20(3):169-177. PMID: 36607347
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Docetaxel.
Cortes JE, Pazdur R
J Clin Oncol 1995 Oct;13(10):2643-55. doi: 10.1200/JCO.1995.13.10.2643. PMID: 7595719

Recent systematic reviews

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A, Park R, Sun W
J Hematol Oncol 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0. PMID: 33436042Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article
Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review.
Laila B, Vinciane L, Michael V, Patrick F, Awada A, Maria GG, Gabriel L
Surg Oncol 2020 Dec;35:520-526. Epub 2020 Oct 21 doi: 10.1016/j.suronc.2020.10.014. PMID: 33157433

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...